Actively Recruiting
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
Led by Verve Therapeutics, Inc. · Updated on 2026-04-28
36
Participants Needed
10
Research Sites
161 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.
CONDITIONS
Official Title
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Refractory hypercholesterolemia
- Refractory hypertriglyceridemia
- Age between 18 and 70 years
You will not qualify if you...
- Active or history of chronic liver disease
- Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe
- Clinically significant or abnormal laboratory values as defined by the protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Clinical Study Center
Adelaide, Australia
Actively Recruiting
2
Clinical Study Center
Melbourne, Australia
Actively Recruiting
3
Clinical Study Center
Chicoutimi, Canada
Actively Recruiting
4
Clinical Study Center
Montreal, Canada
Actively Recruiting
5
Clinical Study Center
Toronto, Canada
Actively Recruiting
6
Clinical Study Center
Cape Town, South Africa
Actively Recruiting
7
Clinical Study Center
Johannesburg, South Africa
Actively Recruiting
8
Clinical Study Center
Liverpool, United Kingdom
Actively Recruiting
9
Clinical Study Center
London, United Kingdom
Actively Recruiting
10
Clinical Study Center
Manchester, United Kingdom
Actively Recruiting
Research Team
C
Clinical Development
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here